Business Wire

ABILIFY® (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY® (aripiprazole) Injection, an injectable ...
Medscape

Intramuscular Aripiprazole May Be Effective Against Acute Agitation in Psychosis

Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...
Business Wire

Results from a Phase 3 Study of Once-Monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting ...

Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...
Medscape

Long-term Injectable Drug Effective for Schizophrenia

May 11, 2012 (Philadelphia, Pennsylvania) — Intramuscular depot aripiprazole is a safe and tolerable option for long-term maintenance treatment of schizophrenia, according to several presentations ...
FiercePharma

U.S. FDA Approves Dual-Chamber Syringe for Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension for the Treatment of Schizophrenia

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...
Monthly Prescribing Reference

Phase 3 Study of Aripiprazole Intramuscular Depot for the Maintenance Treatment of Schizophrenia

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the ...
FiercePharma

Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY – ABILIFY for Extended–release Injectable Suspension, for Intramuscular Use – Indicated for Schizophrenia

ABILIFY extended–release injectable suspension, for intramuscular use, is administered to the patient just once every four weeks. It first became available to patients in the US in March 2013 and is ...
Monthly Prescribing Reference

Results from First-of-Kind Abilify Maintena Study Announced

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Otsuka and Lundbeck announced results from the first-of-its-kind study comparing the effectiveness of aripiprazole ...
Yahoo Finance

Health Canada Approves Otsuka and Lundbeck's (Pr)ABILIFY ASIMTUFII® (aripiprazole), the First-and-Only, Once-Every-Two-Months, Long-Acting Injectable (LAI) Treatment for ...

MONTREAL, Jan. 20, 2025 /CNW/ - Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Canada Inc. (Lundbeck) announce that Health Canada has issued a Notice of Compliance for ABILIFY ASIMTUFII® ...
Healthline

Abilify and Cost: What You Need to Know

Abilify is available in several different brand-name versions: Abilify comes as a tablet that you swallow. Abilify MyCite comes as a tablet with a sensor that you swallow.* Abilify Maintena comes as ...
Medical News Today

Abilify (aripiprazole) and cost

Abilify (aripiprazole) is a brand-name oral tablet prescribed for certain mental health conditions, such as schizophrenia. The cost of Abilify with and without insurance can depend on several factors, ...